An Exploratory, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect and Safety of Pitolisant in Children and Adolescents with Autism Spectrum Disorders
Latest Information Update: 28 Sep 2024
At a glance
- Drugs Pitolisant (Primary)
- Indications Pervasive child development disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Bioprojet
- 19 Sep 2024 Planned End Date changed from 1 Jan 2025 to 1 Nov 2025.
- 19 Sep 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Nov 2025.
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.